Business
LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES
LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DE...
About this update from Lsl Pharma Group Inc
[{"type":"text","content":"\n\n\n\n LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n\n\n\n\n\n\n BOUCHERVILLE, QC\n \n\n ,\n \n\n Aug. 4, 2025\n \n\n /CNW/ -\n \n LSL PHARMA GROUP INC\n \n . (TSXV: LSL) (\"\n \n LSL Pharma\n \n \" or the \"\n \n Corporation\n \n \"), a Canadian integrated pharmaceutical company, today announced that it has completed the early redemption and cancellation of all issued and outstanding 11.0% Unsecured Convertible Debentures (originally scheduled to mature on October 31, 2028) (the \"\n \n Debentures\n \n \").\n \n\n Pursuant to the Company's announcement on July 2, 2025, Debenture holders were paid an aggregate amount of\n \n $3,505,098.08\n \n , representing (i)\n \n $3,288,000\n \n as the principal amount of the Debentures, (ii) the early repayment premium pursuant to the trust indenture dated\n \n November 1, 2023\n \n between the Corporation and the Trustee ,TSX Trust Company and (iii) all accrued and unpaid interest up to but excluding the Redemption Date.\n \n\n As a result of the early redemption, all Debentures, previously listed on the TSX Venture Exchange (\"\n \n TSXV\n \n \") under the symbol LSL.DB, were delisted and have ceased trading on\n \n August 1, 2025\n \n , in accordance with TSXV policies.\n \n\n\n ABOUT LSL PHARMA GROUP INC.\n \n\n\n LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Companies forming part of LSL Pharma Group include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc. and Dermolab Pharma Ltd. For further information, please visit our website at\n \n www.groupelslpharma.com.\n \n\n\n\n CAUTION REGARDING FORWARD-LOOKING STATEMENTS\n \n\n\n This press release may contain forward-looking statements as defined un...